The orally combined neuroprotective effects of sodium ferulate and borneol against transient global ischaemia in C57 BL/6J mice

J Pharm Pharmacol. 2010 Jul;62(7):915-23. doi: 10.1211/jpp.62.07.0013.

Abstract

Objectives: This study aimed to investigate the possible modification of the neuroprotective effect of sodium ferulate, when orally co-administered with borneol, in transient global cerebral ischaemia-induced functional, histological and cellular alterations in mice.

Methods: The bilateral common carotid artery occlusion was conducted in C57 BL/6J mice for 25 min. The mice were then subjected to a water maze test over an extended recovery period, followed by an assessment of neuronal loss in the CA1 region of the hippocampus (haematoxylin and eosin staining). The blood-brain barrier permeability (Evans blue tracing), brain oedema and oxidative stress were assayed and histological sections were also immunostained for gliofibrillar acid protein (GFAP) expression.

Key findings: The ischaemia reperfused mice were associated with long-lasting spatial learning deficits in the absence of other behavioural impairments and with neurodegeneration in the hippocampal CA1 region. However, the histological injuries were significantly attenuated by oral co-administration of sodium ferulate and borneol. Furthermore, combined treatment with sodium ferulate and borneol resulted in a significant reduction in brain oedema, GFAP-positive cells, malonaldialdehyde levels and blood-brain barrier permeability, but an increase in superoxide dismutase activity.

Conclusions: Borneol may have benefits for the neuroprotective effect of sodium ferulate against injury induced in the brain by ischaemia/reperfusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood-Brain Barrier / drug effects
  • CA1 Region, Hippocampal / drug effects*
  • CA1 Region, Hippocampal / metabolism
  • CA1 Region, Hippocampal / pathology
  • Camphanes / administration & dosage
  • Camphanes / pharmacology
  • Camphanes / therapeutic use*
  • Carotid Arteries
  • Cerebrovascular Disorders
  • Coumaric Acids / administration & dosage
  • Coumaric Acids / pharmacology
  • Coumaric Acids / therapeutic use*
  • Drug Therapy, Combination
  • Edema / drug therapy
  • Glial Fibrillary Acidic Protein
  • Ischemic Attack, Transient / drug therapy*
  • Ischemic Attack, Transient / metabolism
  • Ischemic Attack, Transient / pathology
  • Learning
  • Male
  • Malondialdehyde / metabolism
  • Maze Learning
  • Mice
  • Mice, Inbred C57BL
  • Nerve Tissue Proteins / metabolism
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Permeability
  • Plant Extracts / administration & dosage
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use*
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / pathology
  • Superoxide Dismutase / metabolism

Substances

  • Camphanes
  • Coumaric Acids
  • Glial Fibrillary Acidic Protein
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Plant Extracts
  • glial fibrillary astrocytic protein, mouse
  • Malondialdehyde
  • ferulic acid
  • Superoxide Dismutase
  • isoborneol